Colorectal cancer is one of the most common malignancies in the Western world, and even after surgical removal, there is a high recurrence rate. Metformin treatment has been associated with a reduced risk of developing cancer, but whether metformin influences the risk of recurrence is unknown. The aim of our study was to examine the association between treatment with metformin and recurrence-free, disease-free survival and all-cause mortality after surgery for colorectal cancer. The study was an observational register-based study and included 25,785 patients, of which 1,116 had medically treated diabetes and 966 started metformin treatment at some point postoperatively. Diabetes was not associated with neither disease-free (HR adjusted 5 1.09, 95% CI 0.97-1.21, p 5 0.15) nor recurrence-free survival (HR adjusted 5 1.13, 95% CI 0.95-1.35, p 5 0.17). The study found no difference in regards to disease-free or recurrence-free survival between the metformin treated group (HR RFS 5 1.06, 95% CI 0.87-1.15, p 5 0.57, HR DFS 5 1.01, 95% CI 0.89-1.15, p 5 0.85) and non-diabetic patients. Patients with diabetes had increased all-cause mortality (HR adjusted 5 1.29, 95% CI 1.16-1.45, p < 0.0001). Metformin treatment did not affect all-cause mortality (HR 5 1.07, 95% CI 0.94-1.22, p 5 0.33) compared to non-diabetic patients. In conclusion, our study did not find an association between diabetes or metformin treatment and recurrence-free or disease-free survival after surgery for colorectal cancer. However, diagnosis of diabetes is associated with increased all-cause mortality.
Introduction
Diabetes mellitus and colorectal cancer share several risk factors including obesity and physical inactivity, and diabetes is proven to be an independent risk factor for developing colorectal cancer. 1, 2 Several studies have shown that patients with both colorectal cancer and diabetes have a lower survival compared to patients without diabetes, [3] [4] [5] [6] [7] [8] whereas other studies have reported no association. 9, 10 Metformin is the drug of choice for treatment of type 2 diabetes. Previous, several studies indicate that metformin may decrease the risk of developing certain cancers including colorectal cancer, [11] [12] [13] however recently a large retrospective study have not been able to show any association between metformin and cancer risk. 14 The antineoplastic molecular action of metformin is believed to work through the inhibition of the mammalian target of the rapamycin (mTOR) pathway. 15 This pathway has a central role in regulating basic cell behaviors such as regulation of protein synthesis and cell growth as well as cell survival, metabolism and cytoskeletal organization. [16] [17] [18] Although studies show that metformin has an antineoplastic effect and can inhibit cancer cell growth, 15, 19 few studies have examined the potential survival benefits in colorectal cancer patients with diabetes who are receiving metformin, 12, [20] [21] [22] [23] [24] [25] and only one study has investigated the risk of recurrence after colorectal cancer. 9 The few studies conducted have used metformin as a never/ever time fixed variable and only examined the pre-diagnostic use. 20, 23 Some of the studies have suffered from immortal time bias, 25 which occurs when unexposed time before exposure start is misclassified as exposed thereby falsely exaggerate the benefits of metformin. 26 The aim of our study was to examine the association between treatment with metformin initiated after surgery for colorectal cancer and recurrence-free, disease-free survival and all-cause mortality.
Materials and Methods

Study cohort
Patients who were undergoing curative resection or endoscopic resection (such as endoscopic mucosa resection or endoscopic submucosal dissection) for colorectal cancer between January 1, 2004 and July 1, 2015 in Denmark were identified through the Danish Colorectal Cancer Group national clinical register (DCCG).
The DCCG contains detailed information regarding demographic factors, comorbidity, peri-and postoperative treatment and 98.6% of all patients diagnosed with colorectal cancer are included. 27 From this database, we obtained infor- ), blood transfusion in the perioperative period (whether it occurred or not), tumor classification (TNM), operative procedure (type of resection and endoscopic procedures), type of surgery (emergency or elective surgery) and date of surgery. All information from DCCG was assessed at time of surgery.
All Danish residents have a unique personal identification number (CPR-number) and information on immigration, emigration and mortality among all patients is recorded in the Danish Civil Registration System. The Danish Civil Registration system is complete, and no persons are lost to follow up. 28 The unique CPR-number makes it possible to link the registers used. All hospital contacts including outpatient visits are registered in the Danish National Patient Register (NPR). 29 Information regarding hospital admission such as date of admission and discharge, procedure codes and diagnoses were obtained from the NPR. Danish Pathology Departments have recorded standard data on biological specimens and specimens are coded using the Danish version of the Systemized Nomenclature of Medicine (SNOMED) codes. Pathologically diagnosed recurrences are documented in the Danish Pathology Register (DPR) 30 using SNOMED codes.
Assessment of diabetes and exposure data
Prescribed drugs dispensed at the Danish community pharmacies since 1995 are registered in The Danish National Prescription Register (DNPR). 31 All redeemed prescriptions for antidiabetic medication (Anatomical Therapeutic Chemical code (ATC-code), A10) for each study participant 1 year before surgery for colorectal cancer and until end of followup were identified. Diabetes was defined as medically treated diabetes, because information regarding diet-treated diabetes is not available in the registers used. Regarding antidiabetic medication, patients with diabetes were classified into the following groups: (1) metformin alone or in combination with other antidiabetic medication, (2) insulin alone or in combination with other antidiabetic medication (not metformin) and (3) other oral antidiabetic medication. Patients with contacts to the hospital or an outpatient clinic with International Classification of Diseases 10th version (ICD 10) codes associated with diabetes with complications (E10-14 excluding E109, E119, E129, E139 and E149) were identified from the NPR. Thereby, information on the severity of diabetes was available.
The exposure to antidiabetic medication during follow-up after surgery were estimated using the date and WHO's defined daily doses (DDD) for each prescription, and included as a time-varying covariate to avoid immortal time bias. Drug use after surgery had the potential to vary for every month of follow-up. The cohort was followed from 180 days after surgery until death (by any cause), occurrence of relapse or end of observation (December 31, 2015) .
To examine the dosage of metformin, the metformin group was further categorized in the following groups: (1) 1-75 DDD/years at risk, (2) 75-199 DDD/years at risk and (3) 200 DDD/years at risk metformin.
Study design
Patients who were diagnosed with diabetes and redeemed prescriptions for antidiabetic medication in the year preceding surgery were excluded in the main analysis. This was done to emulate a randomized trial study design, 32 and only examine incident patients with diabetes and na€ ıve users of antidiabetic medication. Patients who died within 180 days after surgery and patients with metastases at time of surgery or within 180 days after surgery were excluded, as it was not relevant to investigate recurrence in these patients. Furthermore, the 180 day limit was a criteria in the validated algorithm used to investigate recurrence described below. Moreover, patients with other cancer diagnoses (except non-melanoma skin cancer) before the date of colorectal cancer diagnosis were excluded as the NPR registered metastases codes listed below do not distinguish between which primary cancer the metastasis was due to.
What's new?
Evidence suggests that metformin, a drug commonly used to treat type 2 diabetes, can potentially lower colorectal cancer risk. Whether metformin is also associated with improved survival or reduced risk of recurrence in colorectal cancer is unclear. The present study examined the effects of metformin treatment initiated after surgery for colorectal cancer in diabetes patients. No association was found between metformin treatment and recurrence-free or disease-free survival. Colorectal cancer patients with diabetes generally had poorer survival compared with their nondiabetic counterparts. All-cause mortality was significantly increased for patients taking oral antidiabetic medications other than metformin.
Recurrence during follow-up was estimated using a validated algorithm described in detail elsewhere. 33 In brief, at least one of the following criteria must be met:
NPR-registered metastases code 180 days after the first colorectal cancer surgery, and without a new primary cancer diagnosis between the date of colorectal cancer surgery and date of metastases code. NPR-registered cytostatic therapy codes 180 or more days after the first colorectal cancer surgery and 60 or more days after the last cytostatic therapy code, and without a new primary tumor in the time period between colorectal cancer surgery and date of cytostatic therapy code. DPR-registered SNOMED combinations indicating recurrence recorded 180 or more days after the first colorectal cancer surgery, and without a new primary cancer diagnosis. A code specific for local colorectal cancer recurrence in the NPR any time after primary diagnosis: DC189X and DC209X. These codes have only been used in NPR since the beginning of 2012.
Statistical methods
A Cox regression model was used to estimate all-cause mortality, recurrence-free and disease-free survival. In our study, disease-free survival was defined as time from 180 days after surgery to time of recurrence, new primary tumor or death by any cause. Recurrence-free survival was defined as time from 180 days after surgery to diagnosis of recurrence.
Patients were censored if a new primary tumor occurred or death from any cause. Overall mortality was the time from 180 days after surgery to time of death regardless of cause. The models were adjusted for age at diagnosis, sex, Charlson comorbidity index, BMI, blood transfusions, smoking, alcohol consumption, elective or emergency surgery, type of cancer (colon or rectum), T-stage, lymph node status, diabetic complications, year of surgery and years after surgery. Results were presented as hazard ratios (HR) with 95% confidence intervals (95% CI) and p-values below 0.05 were considered statistically significant. Regarding the recurrence-free survival, competing risk analyses were performed using the method proposed by Fine and Gray. 34 
Sensitivity analyses
Five separate pre-planned sensitivity analyses were conducted, repeating the primary analysis using five restrictions:
(1) antidiabetic medication was only evaluated in a 6-month period before the time of risk. (2) To create a homogenous group, we limited our analysis to those with lower comorbidities (Charlson comorbidity index 0 and 1 35 All statistical analyses were performed using the SAS V R Proprietary Software 9.4, SAS Institute, Inc., Cary, NC.
Results
A total of 25,785 patients were included in the study, of which 1,116 had medically treated diabetes at some point postoperatively, and of those, 966 were treated with metformin (Fig. 1) .The median follow-up time was 3.6 years (Maximum was 12.5 years and the minimum was 1 day). In the follow-up period, a total of 7,877 patients died and 5,527 were diagnosed with recurrence. In general, patients with medical treated diabetes had a higher BMI and were more comorbid, compared to the non-diabetes group. However, there were no differences in regards to T-stage, but more patients had node negative tumors in the metformin and insulin treated groups (Table 1) .
Disease-free and recurrence-free survival
Diabetes was not associated with neither disease-free (HR adjusted 5 1.09, 95% CI 0.97-1.21, p 5 0.15) nor recurrencefree survival (HR adjusted 5 1.13, 95% CI 0.95-1.35, p 5 0.17). No difference in regards to disease-free or recurrence-free survival was shown between the metformin treated group, or patients receiving other oral antidiabetic medication, and the patients not diagnosed with medical treated diabetes. Insulin treatment were associated with a poorer disease-free survival (HR adjusted 5 1.63, 95% CI 1.17-2.26, p 5 0.004) but no difference in recurrence-free survival when compared to non-diabetes patients ( Table 2 , Fig. 2 ). Competing risk analysis regarding recurrence-free survival and metformin treatment found a subdistribution hazard ratio of 1.06 (p 5 0.57) and for insulin users the subdistribution hazard ratio of 1.41 (p 5 0.21).
All-cause mortality
Patients with diabetes had a statistical significant increased all-cause mortality (HR adjusted 5 1.29, 95% CI 1.16-1.45, p < 0.0001). Metformin treatment did not affect all-cause mortality compared to non-diabetes patients, whereas treatment with other oral antidiabetic medication and especially insulin showed increased all-cause mortality (HR adjusted 5 1.47, 95% CI 1.16-1.87, p 5 0.002 and HR adjusted 5 3.74, 95% CI 2.99-4.69, p < 0.0001, respectively) ( Table 2) .
Metformin dosage was not associated with any difference in regards to any of the outcomes (Table 3) .
Sensitivity analyses
The sensitivity analyses all found similar results regarding the association between metformin and disease-free-recurrencefree survival and overall mortality (Table 4) .
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Discussion
The study showed no association between diabetes or metformin use and disease-free, recurrence-free survival when compared to non-diabetes patients. Diabetes was associated with increased all-cause mortality, yet metformin use showed no association with all-cause mortality when compared to nondiabetes patients. Other oral antidiabetic medication and especially insulin treatment was associated with worse disease-free survival and all-cause mortality, but not with recurrence-free survival when compared to non-diabetes patients.
In general, patients with diabetes have a poorer survival 3, 36 and increased risk of developing colorectal cancer.
1,37
The increased risk of colorectal cancer is probably due to hyperinsulinemia, 4,38 hyperglycemia and chronic inflammation. 39, 40 Several studies have examined the overall survival in patients with diabetes and colorectal cancer, and most studies found a decreased overall survival. 1, [3] [4] [5] [6] [7] [8] 41 Studies regarding the cancer-specific mortality have shown conflicting results; several studies reported that diabetes increases the cancer-specific mortality, 4,42-44 but some showed no effect. 5, 7, 45 However, the recurrence-free and disease-free survival has been scarcely examined.
Patients with cancer and diabetes may receive less aggressive cancer treatment or less aggressive diabetes care, both of which could compromise survival and risk of recurrence. 8, [46] [47] [48] Furthermore, a lower response rate to chemo-radiotherapy in patients with rectal cancer and diabetes has been reported. 49 It is a possibility that tumor aggressiveness may be influenced by poor glycemic control, 38 hyperinsulinemia and increased levels of insulin-like growth factors. 50 In our study, diabetes and antidiabetic medication was not found to be associated with recurrence-free survival; however, patients treated with insulin had a significant worse overallmortality compared to patients not diagnosed with diabetes. This finding is confirmed in several other studies investigating overall-mortality in patients with diabetes. 51, 52 Generally, patients with insulin-treated diabetes tend to have more severe diabetes and of longer duration, both of which are associated with increased risk of colorectal cancer and allcause mortality but not increased cancer-specific mortality. 4 In the main analysis, patients receiving antidiabetic medication in the year preceding surgery were excluded and only na€ ıve users were investigated thereby limiting the bias of insulin users had a longer duration of diabetes compared to metformin users. Yet, even in the analyses including prevalent users no association between metformin use and the survival outcomes. Exogenous insulin is usually commenced at a later state in the natural history of diabetes, and perhaps this is some of the explanation of the increased mortality in the insulin treated patients. Clinical guidelines for treatment of type 2 diabetes recommend that insulin is added to treatment with metformin rather than replacing the existing therapy. Recently a study investigating mortality in patients with diabetes found a decreased mortality in patients receiving insulin plus concomitant metformin compared to patients in insulin monotherapy. 52 In our study, the metformin treated group consisted of both patients in metformin monotherapy and in combination treatment with other antidiabetic medication including insulin. The metformin group in our study had a similar all-cause mortality as patients not diagnosed with diabetes. Patients with colorectal cancer and metformin-treated diabetes appears in other studies to have an improved overall survival 12, 20, 41, 53 when compared to patients receiving other antidiabetic medication. These findings are not consistent when compared to patients not diagnosed with diabetes 54 and the results seen for metformin in the meta-analyses of observational studies have not been replicated in metaanalyses of randomized controlled trials. 55 The association between metformin and improved cancer risk found in observational studies may be due to selection bias and immortal time bias 26, 32 and a recent large retrospective study not suffering from the mentioned biases were not able to show any association between metformin use and cancer risk. 14 To emulate a randomized controlled trial and to avoid immortal time bias, a study design excluding prevalent users and only investigating post-diagnostic use as a timedependent covariate were chosen. Furthermore, to avoid confounding by indication, the multivariate analyses were adjusted for the mentioned confounding variables, and several sensitivity analyses were conducted. All of the sensitivity analyses supported the results of the primary analysis.
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To our knowledge, only a few studies have examined the post-diagnostic metformin exposure in patients with colorectal cancer in regard to survival benefits. 53, 54 One of the studies had a problem of immortal time bias, 53 the other study 54 found, in concordance with our study, no protective association between metformin and survival in patients with colorectal cancer. 
Fransgaard et al. There are several limitations in our study. Only patients with medically treated diabetes were characterized as having diabetes because information regarding diet-treated diabetes or the duration of diabetes among the patients with colorectal cancer were not available. Only information regarding redeemed prescription and not actual intake was available. Furthermore, no information regarding glucose, insulin or HbA1c levels was available. Our study is observational which means that unmeasured confounding could have influenced the results. However, the study population is a nationwide unselected population, and the registers used contain multiple important clinically relevant factors including several prognostic factors, thereby limiting the influence of unmeasured confounding and the risk of selection bias.
Potential survival benefits in metformin-users have been observed in other malignancies including breast, upper gastrointestinal, prostate, lung and gynecological cancers. 24, 25, 56 There is a biological plausibility for a cancer protective effect of metformin, given the multiple ways it can interfere with cancer promoting signaling pathways. Nevertheless, epidemiological and animal studies have found mixed effects. However, it remains unclear whether a protective effect can be seen in individuals not diagnosed with diabetes. In the near future, randomized controlled trials should be carried out exploring this area of research with a potential therapeutic role in non-diabetic patients also.
In conclusion, our study did not find an association between diabetes or metformin treatment and recurrence-free or disease-free survival after surgery for colorectal cancer. However, diagnosis of diabetes is associated with increased all-cause mortality. Moreover, the study showed a worse overall survival in patients receiving other oral antidiabetic medication and especially insulin treatment compared to patients not diagnosed with diabetes.
